SEC Form 4 · accession 0001209191-18-019523
U S PHYSICAL THERAPY INC /NV · USPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Glenn McDowell
Officer — Chief Operating Officer
Period of report
Mar 12, 2018
Accepted (ET)
Mar 14, 2018 · 3:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000885978
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Mar 12, 2018 | S | 2,538 | $86.16 | D | 31,219 | D | |
| Common StockF3,F2 | Mar 13, 2018 | S | 205 | $85.45 | D | 31,014 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.15 - $86.25, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- F2Includes 26,935 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,102 shares on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,852 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 1,142 shares on each of April 1, July 1 and October 1, 2020; 1,157 shares on January 1, 2021; 632 shares on each of April 1, July 1 and October 1, 2021; and 640 shares on January 1, 2022.
- F3The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.45 - $85.55, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.